Qualigen Therapeutics presents data on RAS inhibitor program

Qualigen Therapeutics announces the presentation of data in two posters at the American Association for Cancer Research, AACR, Special Conference: Targeting RAS. The two posters outlined preclinical studies of the Company’s RAS-targeted program that showed potential anti-RAS activity in both pancreatic and breast cancer models. The conference took place at the Philadelphia Marriott in Philadelphia, Pennsylvania from March 5-8, 2023. Title: A Novel RAS inhibitor for Pancreatic Cancer. Highlights: The study examines anti-RAS activity in a series of RAS inhibitors with a predicted unique interaction region. The compounds, in development at Qualigen Therapeutics, bind wild type KRAS and HRAS, but exhibit preferential binding to specific mutations of KRAS. Investigators observed suppression of mutant RAS signaling and inhibition of 3D cell growth of mutant RAS cell lines with these agents. They also enhanced the effects of both MRTX-1133 against K-RAS G12D cells and had a similar effect on AMG-510 in K-RAS G12C cell lines. According to Qualigen’s Chief Medical Officer, Tariq Arshad, MD, these agents may serve as novel anti-RAS therapeutics with the potential to enhance activity or suppress resistance to these investigational compounds. Title: A Novel RAS Inhibitor for Luminal B and Triple Negative Breast Cancers. Highlights: RAS pathways are frequently hyper-activated in breast cancers, and genetic/ epigenetic inactivation of RAS-negative regulators is common. Qualigen’s novel small molecules bound all three main RAS proteins and suppressed RAS function. This was validated by Microscale Thermophoresis to quantify recombinant protein interaction 3D growth inhibition and protein-based RAS signaling assays demonstration of antitumor effect in vivo against a Luminal B cell line xenograft.